Therapeutic indications in oncology: Emerging features and regulatory dynamics
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference9 articles.
1. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma;Eichler;Nat Rev Drug Discov,2008
2. Patients and the public deserve big changes in evaluation of drugs;Garattini;BMJ,2009
3. Stopping a trial early in oncology: for patients or for industry?;Trotta;Ann Oncol,2008
4. Haematological anticancer drugs in Europe: any added value at the time of approval?;Bertele’;Eur J Clin Pharmacol,2007
5. Accelerated approval of oncology products: a decade of experience;Dagher;J Natl Cancer Inst,2004
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparing supplemental indications for cancer drugs approved in the US and EU;European Journal of Cancer;2024-09
2. Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent;Journal of Clinical Epidemiology;2021-11
3. New challenges in psycho‐oncology: Using drug development methodology to improve survivorship and supportive care intervention trials;Psycho-Oncology;2019-05-20
4. Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration;The Oncologist;2012-12-20
5. Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice;Journal of Clinical Oncology;2011-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3